10 Companies Reflect Market Decline

5. Exact Sciences Corp. (NASDAQ:EXAS)

Shares of Exact Sciences (EXAS) dropped 5.75 percent on Thursday to finish at $50.44 as investors repositioned their portfolios ahead of the release of its full-year 2024 performance next month.

While net income projections have not been indicated, preliminary results released over the weekend said that Exact Sciences expects a double-digit increase for total revenues and screening revenues in the fourth quarter and full year of 2024.

Investors, however, are in a wait-and-see mode, closely watching whether the company has achieved profitability or managed to reduce its net loss for the full year.

In 2023, it can be learned that Exact Sciences reported a $49.8-million net loss, representing $0.27 per share.

Exact Sciences (EXAS) is a leading provider of tests for cancer prevention, early detection and screening, and therapy guidance.